Aftertreated Polymer (e.g., Grafting, Blocking, Etc.) Patents (Class 424/78.17)
-
Publication number: 20110243881Abstract: A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AaXxYy wherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH2—CH2—CO)—, X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula: —R—COO—R?, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R? represents a hydrogen atom or a cation, Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group according to one of the following formulas: —R—O—SO3—R?, —R—N—SO3—R?, —R—SO3—R?, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzyType: ApplicationFiled: June 14, 2011Publication date: October 6, 2011Inventors: Denis Barritault, Jean-Pierre Caruelle
-
MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF
Publication number: 20110243880Abstract: A polynucleotide delivery vehicle comprising a modified polymer is provided herein, the modified polymer having the following formula: in which W1, W2, W3, W4, W5, W6, Z1, Z2, Z3, Z4, Z5, Z9, R1, R2, R3, R4, R5, n1, n2, n3, n4, n5, and n6 are defined herein. Also disclosed are methods of delivering a polynucleotide to the cytoplasm of a selected tissue type or cell type and methods of reducing expression of a gene in a cell or a subject in need thereof with the modified polymer.Type: ApplicationFiled: March 28, 2011Publication date: October 6, 2011Applicant: Mersana Therapeutics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Carolina B. Cabral, Charles E. Hammond, Cheri A. Stevenson -
Publication number: 20110244001Abstract: A composite material containing polymeric nanofibers, themselves containing NO-donor molecules, imbibed with an elastomer matrix is permeable to both water and gas so that dissociation reactions in the presence of water releases NO gas in a sustained manner. The NO-donor nanofibers may be formed by synthesizing acceptable NO-donor molecules, blending such molecules in solution with PVP, PCL or PVAc, electrospinning the blend at relatively high voltage for form fiber mats, applying PDMS rubber to the fiber mat and crosslinking it. The resulting NO-releasing electrospun fiber composite may be used in medical devices such as catheters, stents, or vascular grafts, with the purpose of releasing nitric oxide within a controlled rate and for a sustained period of time, as well as other known medical applications for NO.Type: ApplicationFiled: April 6, 2011Publication date: October 6, 2011Applicant: Syracuse UniversityInventors: Patrick Mather, Ifeanyi Onyejewke, Kazuki Ishida
-
Publication number: 20110236343Abstract: Polysiloxane-based materials, which include metal species, are provided. The polysiloxane-based compositions and materials generally include (i) amino-functional polysiloxane material and (ii) a plurality of metal species distributed within the polymeric material. Polymer based compositions in which the amino-functional polysiloxane material includes quaternary ammonium groups, e.g., tetraalkyl ammonium groups, are examples of suitable materials which may be used to form the present compositions. The metal species, which may be in an oxidized and/or neutral state, may be bonded, coordinated, chelated, suspended, and/or dispersed within the polymeric material.Type: ApplicationFiled: March 25, 2010Publication date: September 29, 2011Inventors: Bret Ja Chisholm, Partha Majumdar
-
Publication number: 20110223127Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.Type: ApplicationFiled: August 6, 2008Publication date: September 15, 2011Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Patent number: 8012463Abstract: A coordinate complex of diaminocyclohexane platinum (II) with a block copolymer comprising a poly(ethylene glycol) segment and a poly(carboxylic acid) segment is provided. The complex can be effectively used in treatments for tumors, in particular malignant tumors.Type: GrantFiled: December 8, 2004Date of Patent: September 6, 2011Assignee: Toudai TLO, Ltd.Inventors: Kazunori Kataoka, Nobuhiro Nishiyama, Horacio Cabral, Soichiro Okazaki
-
Publication number: 20110212152Abstract: Methods for making modified surfaces and in particular, surfaces that may be lubricious and may be further treated to be anti-microbial are disclosed. Devices comprising modified surfaces prepared by the methods are also disclosed. An exemplary method comprises incubating a photo-initiator-coated substrate in an aqueous monomer solution that is capable of free radical polymerization, exposing the incubating substrate to ultraviolet (UV) light creating a modified surface on the substrate. An anti-microbial agent may be added to the modified surface.Type: ApplicationFiled: December 30, 2010Publication date: September 1, 2011Inventors: Valerio Ditizio, Frank DiCosmo
-
Publication number: 20110212048Abstract: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions.Type: ApplicationFiled: April 29, 2011Publication date: September 1, 2011Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Julia Y. Ljubimova, Keith Black, Eggehard Holler
-
Publication number: 20110212049Abstract: The present disclosure provides injectable synthetic and biodegradable polymeric biomaterials that effectively prevent seroma, a common postoperative complication following ablative and reconstructive surgeries. Provided biomaterials include physically crosslinked hydrogels that are thixotropic, display rapid chain relaxation, are easily extruded through narrow gauge needles, biodegrade into inert products, are well tolerated by soft tissues, and effectively prevent seroma in a radical breast mastectomy animal model.Type: ApplicationFiled: November 3, 2009Publication date: September 1, 2011Applicant: CORNELL UNIVERSITYInventors: David Putnam, Peter Zaweneh, Jason Spector
-
Publication number: 20110212047Abstract: Methods are provided for the treatment of chronic microvascular diseases characterized by inflammation, such as age-related macular degeneration, by administering a polyoxyethylene/polyoxypropylene copolymer. Although a single dose can be effective, multiple treatments can be administered to achieve an optimal and sustained effect. Preferably, a single administration followed by repeated weekly administration of the pharmaceutical composition, but not continuous infusion, achieves a desired effect. Methods of diagnosis and characterization of chronic microvascular diseases using the copolymer are also provided.Type: ApplicationFiled: August 11, 2008Publication date: September 1, 2011Applicant: Synth Rx, Inc.Inventors: Robert L. Hunter, Martin Emanuele
-
Publication number: 20110206634Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: ApplicationFiled: May 3, 2011Publication date: August 25, 2011Applicant: SYNTHASOME, INC.Inventor: Anthony Ratcliffe
-
Publication number: 20110206753Abstract: The present invention relates to processes for the preparation of surface-modified nanoparticulate copper compounds and of aqueous suspensions which comprise surface-modified nanoparticulate copper compounds. The invention furthermore relates to the surface-modified nanoparticulate copper compounds obtainable by these processes and aqueous suspensions of these copper compounds and their use as an antimicrobial active substance or catalyst.Type: ApplicationFiled: July 2, 2009Publication date: August 25, 2011Inventors: Andrey Karpov, Hartmut Hibst, Michael Triller, Eike Hupe, Michael Maier, Jörg Habicht
-
Publication number: 20110206633Abstract: The invention provides CD-NP peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: August 25, 2011Applicant: Nektar TherapecticsInventor: Mary J. Bossard
-
Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic
Publication number: 20110200655Abstract: A medical product is provided that is selected from at least one of, nasal cannulas, oxygen masks, wound dressings, bandages, band aids, catheters, endotrachial tubes, condoms, surgical and other gloves, sheaths for endoscopy probes, and medical products that physically touch the body. A coating is included with at least one of, a non-antibiotic, antimicrobial and/or antiviral substance that prevents further local, non-systemic, colonization of infections.Type: ApplicationFiled: February 16, 2011Publication date: August 18, 2011Inventors: Michael Darryl Black, Anita Margarette Chambers -
Publication number: 20110200550Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.Type: ApplicationFiled: August 11, 2009Publication date: August 18, 2011Applicant: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
-
Patent number: 7998925Abstract: Methods for modification of tissue using covalent chemistry. Tissue can be modified through direct alkylation, reduction followed by alkylation, or oxidation followed by condensation to covalently attach small organic molecules or appropriately modified proteins. The modification can be spatially limited to desired regions of the tissue surface.Type: GrantFiled: September 28, 2005Date of Patent: August 16, 2011Assignee: Baylor UniversityInventors: Robert R. Kane, Aruna Perera
-
Publication number: 20110195104Abstract: Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, and methods for making and using the cationic polymers and surfaces. The cationic polymers include counterions and/or hydrolyzable groups that release active agents.Type: ApplicationFiled: October 14, 2010Publication date: August 11, 2011Applicant: UNIVERSITY OF WASHINGTONInventors: Shaoyi Jiang, Gang Cheng, Luo Mi, Hong Xue, Yuting Li
-
Publication number: 20110195844Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: BASF SEInventors: Bernd Bruchmann, Holger Türk, Daniel Schönfelder, Monika Haberecht, Dietmar Appelhans, Victor Boyko
-
Publication number: 20110195041Abstract: Provided are antimicrobial compositions including at least one biocide covalently bound to a polyurethane. The biocide moiety may comprise triclosan, a triclosan derivative, or a quaternary ammonium salt. Further provided are methods of reducing biofilm formation or microbial growth on a surface, the method including applying to the surface an antimicrobial composition including at least one biocide covalently attached to a polyurethane.Type: ApplicationFiled: October 12, 2009Publication date: August 11, 2011Applicant: NDSU RESEARCH FOUNDATIONInventors: Bret Ja Chisholm, Dean C. Webster, Alexander John Kugel
-
Publication number: 20110189092Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: September 29, 2010Publication date: August 4, 2011Inventors: Scott Eliasof, Thomas C. Crawford, Geeti Gangal, Lawrence Alan Reiter, Pei-Sze Ng
-
Publication number: 20110182951Abstract: The present invention relates to an article comprising a substrate and a coating thereon comprising a complex of an ionic fluoropolymer and a counter-ionic agent comprising ions having antimicrobial activity, to a process for the production of a coating on a polymeric substrate comprising the steps of a) preparing a mixture of an ionic fluoropolymer or a precursor thereof and a counter-ionic agent comprising ions having antimicrobial activity or a precursor thereof and b) applying the mixture prepared in step a) onto the substrate, to the use of such articles for the manufacture of i.a. a garment, a filter element, a venting element or a protective enclosure, and to the use of a coating composition comprising a complex of an ionic fluoropolymer and a counter-ionic agent comprising ions having antimicrobial activity as an antimicrobial coating of a substrate.Type: ApplicationFiled: July 15, 2009Publication date: July 28, 2011Inventors: Wolfgang Burger, Rudolf Steffl
-
Publication number: 20110171163Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: Nektar TherapeuticsInventors: Dawei Sheng, Harold Zappe, C. Simone Jude-Fishburn, Steven O. Roczniak, Mary J. Bossard
-
Publication number: 20110171164Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: Nektar TherapeuticsInventors: Mary J. Bossard, Steven O. Roczniak, Cherie F. Ali
-
Publication number: 20110171161Abstract: The invention provides protegrin that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention has enhanced half-life and/or reduced clearance.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: Nektar TherapeuticsInventors: Yujun Wang, Haim Moskowitz, Xiaofeng Liu, Steven O. Roczniak, Mary J. Bossard
-
Publication number: 20110171166Abstract: The invention provides osteocalcin that is chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Inventors: Steven O. Roczniak, Cherie F. Ali
-
Publication number: 20110171165Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Inventors: Dennis G. Fry, Christine Taylor Brew, Steven O. Roczniak, Xiaofeng Liu
-
Publication number: 20110171160Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: Nektar TherapeuticsInventors: Elizabeth Louise Minamitani, Harold Zappe, Mary J. Bossard, Steven O. Roczniak, Xiaofeng Liu
-
Publication number: 20110171162Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 14, 2011Applicant: NEKTAR THERAPEUTICSInventors: Harold Zappe, Mary J. Bossard
-
Publication number: 20110165112Abstract: The invention provides pro insulin c-peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 7, 2011Applicant: Nektar TherapeuticsInventors: Mary J. Bossard, Dennis G. Fry, Steven O. Roczniak, Cherie F. Ali, Haim Moskowitz
-
Publication number: 20110165244Abstract: Elutable coatings and materials comprising protein resistant polymer components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus. Medical devices formed from elutable materials comprised of protein resistant polymer components and bioactive agents are also disclosed. The elutable materials comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus.Type: ApplicationFiled: December 28, 2010Publication date: July 7, 2011Applicant: ALLVIVO VASCULAR, INC.Inventor: Jennifer A. Neff
-
Publication number: 20110165111Abstract: The invention provides nesiritide that is chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of nesiritide not attached to the water-soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 7, 2011Applicant: NEKTAR THERAPEUTICSInventors: Harold Zappe, Mary J. Bossard
-
Publication number: 20110165113Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: July 7, 2011Applicant: Nektar TherapeuticsInventors: Steven O. Roczniak, Ping Zhang, Haim Moskowitz
-
Publication number: 20110165114Abstract: There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition.Type: ApplicationFiled: May 28, 2009Publication date: July 7, 2011Inventors: Colin Peter McCoy, Sean Patrick Gorman, David Simon Jones
-
Publication number: 20110150820Abstract: Conjugates of polypeptides and a polymeric moiety such as PEG covalently attached to the sulfur atom of a methionine side chain are disclosed. Processes of preparing such conjugates, including intermediates and reagents utilized therefore are also disclosed. Further disclosed are therapeutic uses of these conjugates.Type: ApplicationFiled: August 27, 2009Publication date: June 23, 2011Applicant: Insight Biopharmaceuticals Ltd.Inventors: Joel M. Van Gelder, Andrei Serban, Susanna Tchilibon, Daphna Miron
-
Publication number: 20110142787Abstract: A method of covalently bonding a cyclic nitroxide radical compound to a hydrophobic block of a specific hydrophylic-phobic block copolymer, and polymerized cyclic nitroxide radical compound copolymerized in this manner, as well as use of such a compound, for instance, in the medical field are provided. The compound demonstrates long term stability in vivo under reductive environment.Type: ApplicationFiled: December 4, 2008Publication date: June 16, 2011Inventors: Yukio Nagasaki, Toru Yoshitomi, Hirofumi Matsui, Aki Hirayama, Takashi Mamiya, Akira Matsumura, Kensuke Suzuki, Hideo Tsurushima, Aiki Marushima, Kazuko Toh, Daisuke Miyamoto
-
Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent
Publication number: 20110135736Abstract: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.Type: ApplicationFiled: November 26, 2008Publication date: June 9, 2011Inventors: Michael W. Stewart, Roland H. Person, Irwin J. Griffith, Paul B. Tiege, Antoine Noujiam, Bruce Hirsche -
Publication number: 20110135700Abstract: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which essentially all of hydroxyl groups are capped with polyisocyanate.Type: ApplicationFiled: January 31, 2011Publication date: June 9, 2011Applicant: PROMETHEAN SURGICAL DEVICES, INC.Inventor: Michael T. Milbocker
-
Patent number: 7955594Abstract: An alternating copolymer comprising a backbone of residues of a maleic anhydride derivative and those of a compound containing vinylic unsaturation, which also comprises residues of an active compound containing a nucleophilic group, bound to the backbone by a residue of the nucleophilic group, including such copolymer comprising residues of an active compound containing alcohol, thiol or amine group. The chemical and biological propertieis of actives, such as protease inhibitors, neurotransmitter drugs, and other small molecule active drugs, are enhanced, and new applications enabled.Type: GrantFiled: September 25, 2002Date of Patent: June 7, 2011Assignee: Smith & Nephew, PLCInventor: Bryan Greener
-
Publication number: 20110123458Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).Type: ApplicationFiled: June 26, 2009Publication date: May 26, 2011Applicant: Japan Science and Technology AgencyInventors: KazunoriI Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
-
Publication number: 20110123592Abstract: The invention relates to a biomaterial having a latent form of a growth factor immobilised thereon, and to a method of producing the biomaterial, comprising immobilising the latent form of the growth factor on the biomaterial. The biomaterial may be used in medicine, such as in tissue regeneration or repair.Type: ApplicationFiled: May 27, 2009Publication date: May 26, 2011Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Molly Stevens, Jose Sardinha, Erh-Hsuin Lim
-
Patent number: 7947263Abstract: Biocompatible synthetic macromer compositions are provided including a first polymer having multiple functional groups and a second functionalized polyurethane prepolymer, which can be employed as an adhesive or sealant for medical/surgical uses.Type: GrantFiled: December 6, 2006Date of Patent: May 24, 2011Assignee: Tyco Healthcare Group LPInventors: Ahmad R. Hadba, Nadya Belcheva, John Kennedy, Mark Roby
-
Publication number: 20110117167Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Isaac Gilliam Sanford, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Yuchen Chen, Martyn Kerry Darby, Hanne Gron, Ganesan Sathya
-
Publication number: 20110110881Abstract: A liquid composition containing a polymer micelle and having a pH values of 3.0 to 7.0 is provided. The micelle is constituted of a coordination compound having a block copolymer of polyethylene glycol and polyglutamic acid and cisplatin that is coordinate-bonded to the block copolymer.Type: ApplicationFiled: May 27, 2009Publication date: May 12, 2011Inventors: Kazunori Kataoka, Nobuhiro Nishiyama, Chieko Tsuchiya, Tatsuyuki Hayashi
-
Patent number: 7939489Abstract: There are provided topical compositions and methods for cleaning oil from the skin, nail or hair. The compositions have a vehicle and an effective amount of an oil-absorbing ingredient having an ethylene mixed block copolymer. There is also provided compositions and methods for treating acne, acne-related conditions, acne-prone skin and blemishes.Type: GrantFiled: December 23, 2002Date of Patent: May 10, 2011Assignee: Avon Products, Inc.Inventors: Arvind Shah, Gopinathan K. Menon, Derrick B. McKie, Vincent T. Polywoda, Christos D. Kyrou, Michele C. Duggan
-
Publication number: 20110097406Abstract: The present invention provides cell-laden and/or extracellular matrix material laden hydrogels for use in tissue engineering and methods for producing such hydrogels. In some particular embodiments, hydrogels comprise chondrocytes, which are typically encapsulated within the hydrogels. In many instances, such hydrogels are subjected to dynamic loading prior to being administered to a subject to treat a clinical condition that is helped by tissue engineering, including, but not limited to, cosmetic surgery such as craniofacial reconstruction surgery, and cartilage regeneration.Type: ApplicationFiled: October 25, 2010Publication date: April 28, 2011Applicant: The Regents of the University of Colorado, a body CorporateInventors: Stephanie J. Bryant, Garret D. Nicodemus
-
Publication number: 20110081310Abstract: Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating the human body by applying healthcare compositions of the present inventions to the body.Type: ApplicationFiled: October 7, 2009Publication date: April 7, 2011Inventors: Michael J. Fevola, Frank C. Sun, Joseph J. LiBrizzi, Joseph B. Gardner, Russell M. Walters
-
Patent number: 7919076Abstract: Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of ?-amino acids, ?-amino acids, aromatic amino acids or oligopeptides terminated with a molecule of an anthracycline cancerostatic, c) 0.5 to 15% of units of methacryloylated ?-amino acids, ?-amino acids, aromatic amino acids or oligopeptides or their sodium salts.Type: GrantFiled: December 20, 2002Date of Patent: April 5, 2011Assignee: Zentiva, k.s.Inventors: Karel Ulbrich, Tomas Etrych, Blanka Rihova, Marketa Jelinkova, Marek Kovar
-
Publication number: 20110076231Abstract: One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound.Type: ApplicationFiled: April 30, 2010Publication date: March 31, 2011Applicant: PLUROMED, INC.Inventors: Alexander SCHWARZ, Jean RAYMOND
-
Publication number: 20110059010Abstract: The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure (I): wherein each occurrence of M is independently a modifier having a molecular weight ?10 kDa; denotes direct of indirect attachment of M to linker LM; and each occurrence of LM is independently an optionally substituted succinamide-containing linker, whereby the modifier M is directly or indirectly attached to the succinamide linker through an amide bond, and the carrier is linked directly or indirectly to each occurrence of the succinamide linker through an ester bond. In another aspect, the invention provides compositions comprising the conjugates, methods for their preparation, and methods of use thereof in the treatment of various disorder, including, but not limited to cancer.Type: ApplicationFiled: August 19, 2010Publication date: March 10, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Mikhail I. Papisov, Alexander Yurkovetskiy
-
Patent number: 7897698Abstract: The present application discloses a method of modifying a macromolecule, the method comprising the steps of (i) providing the macromolecule; (ii) providing a compound of the general formula (I): wherein N is a primary amino group protected with the protecting group P, wherein the protecting group involves both free valences of the primary amino group; m is an integer of 1-12 and n is an integer of 1-2000; R1 and R2 are independently selected from the group consisting of hydrogen and C1-4-alkyl; and X is a reactive group; and (iii) allowing the compound of the general formula (I) to react with the macromolecule so as to form grafts on the macromolecule. Compounds of the general formula (i) and a method for the preparation thereof are also disclosed.Type: GrantFiled: August 25, 2006Date of Patent: March 1, 2011Assignee: Novo Nordisk A/SInventors: Ib Johannsen, Roice Michael